607729-10-2

Usage

Heterocyclic compound

The compound contains both a pyrazole ring and a pyrimidine ring fused together.

3-(1-methylethyl)group

A group consisting of a carbon atom bonded to a methyl group (CH3) attached to the 3-position of the pyrazole ring.

White to off-white crystalline powder

The physical appearance of the compound is a white to off-white crystalline powder.

Biological activities

The compound has diverse biological activities, including anti-inflammatory, antiviral, and anti-tumor properties.

Potential drug candidate

Due to its various biological activities, the compound is commonly used in pharmaceutical research and development as a potential drug candidate.

Therapeutic agent

The compound has the potential for further investigation as a therapeutic agent for various diseases.

Upstream product

• 521300-03-8 4-amino-5-isopropyl-1⁽²⁾H-pyrazole-3-carboxamide 
• 57-13-6 urea 
• 521300-01-6 5-isopropyl-4-nitro-1⁽²⁾H-pyrazole-3-carboxamide 
• 141721-97-3 5-isopropyl-4-nitro-1⁽²⁾H-pyrazole-3-carboxylic acid 

Downstream Products

• 607728-35-8 N-benzyl-5-chloro-3-isopropyl-1H-pyrazolo[4,3-d]pyrimidin-7-amine 
• 1257628-30-0 7-(2-aminobenzyl)amino-5-chloro-3-isopropylpyrazolo[4,3-d]pyrimidine 
• 1257628-29-7 5-chloro-7-(2-fluorobenzyl)amino-3-isopropylpyrazolo[4,3-d]pyrimidine 

Relevant academic research and scientific papers

Synthesis and biological activity of 8-azapurine and pyrazolo[4,3-d]pyrimidine analogues of myoseverin

The trisubstituted purine myoseverin has been recently identified as a novel inhibitor of microtubule assembly. To analyze the effects of modifying its heterocyclic skeleton, we prepared 8-azapurine and pyrazolo[4,3-d]pyrimidine analogues of myoseverin an

Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy

The invention relates to 3-, 5-, 7-trisubstituted pyrazolo[4,3-d]pyrimidines represented by the general formula I and pharmaceutically acceptable salts thereof, wherein R3 is an optionally substituted alkyl, cycloalkyl, cycloheteroalkyl, cycloalkyl alkyl, aryl or alkylaryl group;R5 is halogen, -NHNH2, -NHOH, NHCONH2, guanylo (NH-C(NH)NH2) an optionally substituted C1-C6 alkyl, alkenyl, alkinyl, C3-C15 cycloalkyl, Rf (C3-C15 cycloalkyl), heterocycle, heteroalkyl, aryl, heteroaryl, arylalkyl, cycloheteroalkyl, cycloheteroalkyl alkyl, heteroarylalkyl group, the group -C(O)-Ra, -C(O)NRbRc, -SO3Rd, or -NHC(O)Re, wherein Ra and Rf are an optionally substituted C1-C6 alkyl, alkenyl, or alkinyl group, Rb, Rc and Rd are independently selected from the group consisting of H, optionally substituted C1-C6 alkyl, alkenyl, or alkinyl group, and Re is a hydroxy, amino, alkoxy, alkylamino, optionally substituted C1-C6 alkyl, alkenyl or alkinyl group; or the group -X-R5', wherein X is -NH-, -O-, -S- or -N(alkyl)- and R5' is hydrogen, an optionally substituted C1-C6 alkyl, alkenyl, alkinyl, C3-C15 cycloalkyl, , Rf(C3-C15 cycloalkyl), aryl, heterocycle, hetero C1-C6 alkyl, arylalkyl, heteroaryl, cycloheteroalkyl, cycloheteroalkyl alkyl, or heteroarylalkyl group, the group -C(O)-Ra, -C(O)NRbRc, -SO3Rd, or -NHC(O)Re, wherein Ra, Rb, Rc, Rd, Re and Rf have the above meaning, andR7 is halogen, -NHNH2, NHOH, NHCONH2, guanylo (NH-C(NH)NH2) or the group -X-R7', wherein X has the above meaning and the meaning of R7' is as defined for R5'.